Saturday 17 October 2026
Export PROK’s income statement to Excel — free account
ProKidney Corp.
PROK Healthcare Biotechnology
ProKidney Corp.’s revenue for fiscal 2025 (year ended December 2025) was $893,000.00, up 1,075.0% from fiscal 2024. In the quarter to June 2026, revenue fell 32.1%, EPS fell 15.4% and free cash flow fell 28.0%, each against the same quarter a year earlier.
1.33
0.13
−8.90%
Follow PROK
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 8.92% | 7.15% | 6.88% | 7.15% |
+8 more TTM periods Free account |
|
| (27.10%) | (20.69%) | (17.77%) | (17.19%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(37.72%) | (27.44%) | (22.91%) | (22.29%) | |
Average Days of Receivables |
426.58 | 423.71 | 460.64 | 0.00 | |
Free Cash Flow per Share |
(0.76) | (0.93) | (0.87) | (1.09) | |
Free Cash Flow |
(141.52) | (131.84) | (117.10) | (146.73) | |
Capital Expenditures |
(0.35) | 0.37 | 3.02 | (34.95) | |
| Other line items | |||||
Cash ROIC |
20.16% | 16.50% | 15.80% | 19.93% | |
Accounts Receivable Turnover |
0.60 | 0.64 | 0.50 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.02 | |
Research and Development Expense of Revenue |
16,004.28% | 13,577.28% | 12,779.73% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
5,760.27% | 5,482.45% | 5,798.10% | 0.00% | |
Share Based Compensation of Revenue |
2,801.71% | 2,684.48% | 2,837.18% | 0.00% | |
Interest Coverage |
(9,327.16) | (8,871.16) | (27,501.17) | (24,458.14) | |
Operating CF/Net income |
1.68 | 1.83 | 1.74 | 1.57 | |
Depreciation/Fixed assets |
0.12 | 0.12 | 0.13 | 0.13 | |
Capex/Depreciation |
(0.05) | 0.06 | 0.46 | (5.54) | |
Revenue per Share |
0.00 | 0.01 | 0.01 | 0.00 | |
Operating CF per Share |
(0.76) | (0.93) | (0.90) | (0.83) | |
Capex per Share |
0.00 | 0.00 | 0.02 | (0.26) | |
Capex to Sales |
0.43 | (0.42) | (3.38) | 0.00 |
Columns are period end dates